Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

Unprecedented demographic shifts toward an aging population are a defining phenomenon of the 21st century, significantly reshaping the landscape of healthcare delivery and resource allocation. Longer ...

Texas company launches sweeping lawsuits against five major players, alleging infringement of medical device patents tied to ...

At the recent ATTD 2025 meeting, participants discussed recent progress and remaining challenges in developing a fully closed ...

In addition to the newsworthy headlines above, the PR Newswire team identified several trends shaping health industry news in ...

The global disposable insulin-delivery device market is projected to experience robust growth over the next decade, according to recent industry insights. Valued at USD 14,585.6 million in 2022, the ...

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use glucose ...

Novo Nordisk A/S NVO on Saturday presented the ... in adults with type 2 diabetes and PAD, at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...